INGM Q3 2026 call: validate margin stability and secondary overhang before any stance change

What happened

Ingram Micro reported Q3 fiscal 2026 results Thursday, with the earnings call transcript now available for review. The Q3 print is the first full quarter after the May 2026 secondary offering that left only $70M in repurchase capacity and after the expected substantial payment of the $6.7M restructuring liability by Q3 2026. Prior to the report, the investment thesis hinged on whether Xvantage-driven SG&A leverage could offset AI-infrastructure gross margin dilution, with Q1 FY2026 showing operating margin declining to 1.60% from 1.64% despite strong sales growth. The master report's monitoring checkpoints required gross margin to stop declining, operating margin to hold at >=1.60%, Xvantage rollout to expand beyond 20 of 57 countries, and ransomware-related corporate costs to no longer be separately cited. Without access to the actual Q3 numbers, the transcript alone does not change the wait-and-see stance, as confirmation of stabilization or deterioration will come from the detailed financials and management commentary.

Implication

Investors should focus on whether Q3 gross margin stopped declining and whether operating margin held at or above 1.60%, as failure to do so would confirm the bear case. Evidence of Xvantage rollout expanding beyond the previously disclosed 20 of 57 countries and SG&A leverage persisting would support the base case, while stalled automation or widening discounts on any new secondary would undermine it. Confirmation that the restructuring liability was substantially paid and ransomware costs no longer appear separately in corporate costs would reduce earnings quality concerns. The remaining $70M repurchase capacity is a key constraint; if no new program expansion is announced and Platinum continues to sell, the overhang persists. Until these data points are clear, the stock remains a show-me story with better entry points likely below $24.

Thesis delta

The Q3 earnings call provides the first test of the Q1 FY2026 margin deterioration against the Xvantage offset thesis, but the article offers no financial details. The prior WAIT rating stands, as we need to verify whether gross margin stabilized, operating margin held >=1.60%, and secondary activity did not intensify. Any confirmation of continued margin decline or aggressive sponsor selling would warrant a downgrade or exit.